Celgene Takes Stake in Regenerative Medicine Company Mesoblast
Celgene has agreed to buy equity in Mesoblast Limited, a Melbourne, Australia-based company specializing in regenerative medicines. Under the agreement, Celgene will purchase 15.3 million ordinary shares in Mesoblast for $45 million. addition, Celgene has a six-month right of first refusal with respect to Mesoblast's proprietary mesenchymal lineage adult stem cell product candidates for the prevention and treatment of acute graft versus host disease (GVHD), certain oncologic diseases, inflammatory bowel diseases, and organ transplant rejection.
Source: Mesoblast Limited